MX2011012659A - Terapia con vacunas para neovascularizacion coroidea. - Google Patents
Terapia con vacunas para neovascularizacion coroidea.Info
- Publication number
- MX2011012659A MX2011012659A MX2011012659A MX2011012659A MX2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A
- Authority
- MX
- Mexico
- Prior art keywords
- neovascularization
- choroidal neovascularization
- vaccine therapy
- vegfr
- peptide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 title 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000035719 Maculopathy Diseases 0.000 abstract 2
- 206010029113 Neovascularisation Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 210000003161 choroid Anatomy 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
- B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
- B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
- B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
- B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
- B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Mechanical Engineering (AREA)
- Aviation & Aerospace Engineering (AREA)
- Transportation (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009140363 | 2009-06-11 | ||
| PCT/JP2010/003871 WO2010143435A1 (en) | 2009-06-11 | 2010-06-10 | Vaccine therapy for choroidal neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012659A true MX2011012659A (es) | 2011-12-16 |
Family
ID=43308696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012659A MX2011012659A (es) | 2009-06-11 | 2010-06-10 | Terapia con vacunas para neovascularizacion coroidea. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8975229B2 (enExample) |
| EP (1) | EP2440226A4 (enExample) |
| JP (1) | JP5688587B2 (enExample) |
| KR (1) | KR20120038419A (enExample) |
| CN (1) | CN102802654A (enExample) |
| AU (1) | AU2010259797B2 (enExample) |
| BR (1) | BRPI1013025A2 (enExample) |
| CA (1) | CA2764562A1 (enExample) |
| IL (1) | IL216402A0 (enExample) |
| MX (1) | MX2011012659A (enExample) |
| RU (1) | RU2555345C2 (enExample) |
| SG (2) | SG10201403109VA (enExample) |
| TW (1) | TW201109029A (enExample) |
| WO (1) | WO2010143435A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289532A1 (en) | 2005-02-28 | 2011-03-02 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| ES2405763T3 (es) * | 2007-02-16 | 2013-06-03 | Oncotherapy Science, Inc. | Vacunoterapia para la neovascularización coroidea |
| FR2990352A1 (fr) | 2012-05-10 | 2013-11-15 | Univ Paris 13 | Composition immunogene comprenant un peptide derive du vegf et ses utilisations |
| CN110612115A (zh) * | 2017-05-19 | 2019-12-24 | 学校法人庆应义塾 | 针对脑神经疾病的肽疫苗和肽疫苗组合物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| JP3734262B2 (ja) | 1993-03-25 | 2006-01-11 | メルク エンド カンパニー インコーポレーテッド | 血管内皮細胞増殖因子阻害剤 |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| US6348333B1 (en) | 1997-01-17 | 2002-02-19 | Toa Gosei Co., Ltd. | VEGF-binding KDR polypeptide |
| JP4405597B2 (ja) | 1997-06-18 | 2010-01-27 | メルク エンド カムパニー インコーポレーテッド | ヒト受容体型チロシンキナーゼｋｄｒ |
| AU2299099A (en) | 1998-02-04 | 1999-08-23 | Kyowa Hakko Kogyo Co. Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| CA2328893A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
| WO2001012809A2 (en) | 1999-08-13 | 2001-02-22 | Crucell Holland B.V. | Heterodimeric vegf variants used for inhibiting angiogenesis |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| AU2002362461A1 (en) | 2001-10-01 | 2003-04-14 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| CU23178A1 (es) | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| EP2267023B1 (en) | 2002-09-12 | 2015-02-11 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
| SI1539157T1 (sl) | 2002-09-18 | 2013-11-29 | Trustees Of The University Of Pennsylvania | Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije |
| ES2687645T3 (es) | 2003-10-27 | 2018-10-26 | Merck Sharp & Dohme Corp. | Método de diseño de ARNip para el silenciamiento de genes |
| JP2006215988A (ja) * | 2005-02-07 | 2006-08-17 | Ntt Docomo Kansai Inc | 認証システム、携帯端末装置及び認証方法 |
| EP2289532A1 (en) | 2005-02-28 | 2011-03-02 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| JP2006315988A (ja) | 2005-05-11 | 2006-11-24 | Mototake Shimizu | ケモカイン産生誘導効果を有する血管新生阻害物質 |
| ES2405763T3 (es) | 2007-02-16 | 2013-06-03 | Oncotherapy Science, Inc. | Vacunoterapia para la neovascularización coroidea |
| JP5272134B2 (ja) | 2007-06-14 | 2013-08-28 | オンコセラピー・サイエンス株式会社 | Ｓｍｙｄ３によるｖｅｇｆｒ１のメチル化調整因子を同定する方法 |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
-
2010
- 2010-06-08 TW TW099118513A patent/TW201109029A/zh unknown
- 2010-06-10 WO PCT/JP2010/003871 patent/WO2010143435A1/en not_active Ceased
- 2010-06-10 MX MX2011012659A patent/MX2011012659A/es active IP Right Grant
- 2010-06-10 EP EP10785967.0A patent/EP2440226A4/en not_active Withdrawn
- 2010-06-10 AU AU2010259797A patent/AU2010259797B2/en not_active Expired - Fee Related
- 2010-06-10 CA CA2764562A patent/CA2764562A1/en not_active Abandoned
- 2010-06-10 RU RU2012100241/15A patent/RU2555345C2/ru not_active IP Right Cessation
- 2010-06-10 SG SG10201403109VA patent/SG10201403109VA/en unknown
- 2010-06-10 CN CN2010800356548A patent/CN102802654A/zh active Pending
- 2010-06-10 BR BRPI1013025A patent/BRPI1013025A2/pt not_active IP Right Cessation
- 2010-06-10 SG SG2011090933A patent/SG176737A1/en unknown
- 2010-06-10 KR KR1020117031702A patent/KR20120038419A/ko not_active Withdrawn
- 2010-06-10 US US13/377,110 patent/US8975229B2/en not_active Expired - Fee Related
- 2010-06-10 JP JP2011552249A patent/JP5688587B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-17 IL IL216402A patent/IL216402A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012529423A (ja) | 2012-11-22 |
| TW201109029A (en) | 2011-03-16 |
| KR20120038419A (ko) | 2012-04-23 |
| EP2440226A1 (en) | 2012-04-18 |
| BRPI1013025A2 (pt) | 2016-04-05 |
| EP2440226A4 (en) | 2013-09-18 |
| IL216402A0 (en) | 2012-01-31 |
| SG176737A1 (en) | 2012-01-30 |
| CA2764562A1 (en) | 2010-12-16 |
| SG10201403109VA (en) | 2014-10-30 |
| WO2010143435A1 (en) | 2010-12-16 |
| JP5688587B2 (ja) | 2015-03-25 |
| RU2012100241A (ru) | 2013-07-20 |
| AU2010259797A1 (en) | 2011-12-08 |
| US20120156233A1 (en) | 2012-06-21 |
| CN102802654A (zh) | 2012-11-28 |
| US8975229B2 (en) | 2015-03-10 |
| RU2555345C2 (ru) | 2015-07-10 |
| AU2010259797B2 (en) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EP2949344A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| WO2009051837A3 (en) | Vaccine nanotechnology | |
| CN107921106A (zh) | Wt1抗原肽和免疫调节剂的组合 | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| PH12015500297A1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MX2019001021A (es) | Formulaciones de liposomas. | |
| BR112015010396A2 (pt) | terapia de combinação | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| JP2017533201A5 (enExample) | ||
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| Amlie-Lefond et al. | Innate immunity for biodefense: a strategy whose time has come | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| SA520411067B1 (ar) | تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة | |
| CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| BR112015013215A2 (pt) | proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares | |
| MX2009008750A (es) | Terapia de vacuna para neovascularizacion coroidal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |